After Hours Summary: NVDA +4.4% higher on earnings/guidance and expanded AWS partnership; OKTA +20.1%, CRM +12.7%, CRWD +11.6%, VEEV +8.1% also higher on earnings; HPQ -8.8%, URBN -2.1% lower on earnings
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: OKTA +20.1%, CRM +12.7% (also launches Claudeforce), LTRX +12.5%, CRWD +11.6%, VEEV +8.1%, NTNX +7.8%, OOMA +7.8%, NVDA +4.4% (also AWS to deploy 2 mln additional NVIDIA GPUs), A +3.2%, P +1.8%,
Companies trading higher in after hours in reaction to news: TENB +8.1% (to join S&P SmallCap 600), FNKO +6.5% (Director bought 72,992 shares at $6.85 worth ~$500K), PAHC +5.7% (to close Chicago Heights manufacturing facility in summer 2027), VISN +4.6% (authorizes additional $150 mln share repurchase), SKHY +4% (NVDA sharply increases commitments, driven largely by memory procurement), SNDK +3.7% (NVDA sharply increases commitments, driven largely by memory procurement), MU +3.2% (NVDA sharply increases commitments, driven largely by memory procurement), NEO +2.8% (gets Medicare coverage expansion for RaDaR ST in immunotherapy monitoring), LRCX +2% (breaks ground on Oregon R&D lab), SPIR +1.9% (wins $28 mln NOAA contract for hyperspectral microwave sounding work), VRRM +1.6% (expands HTZ technology partnership under renewed five-year contract), RVSB +1.6% (authorizes $4.0 mln stock repurchase program), BWXT +1.5% (selected by U.S. Army for Janus microreactor program at Fort Campbell), KRMN +1.2% (names new CFO), HTZ +0.9% (VRRM renews agreement), CASY +0.6% (to join Bloomberg 500 index in September reconstitution), DINO +0.1% (authorizes new $1.5 bln share repurchase program)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: HPQ -8.8%, URBN -2.1%, SNPS -1.6%
Companies trading lower in after hours in reaction to news: WEN -14.8% (report that Trian has no current plans to bid for the company), AXG -3% (announces AI infrastructure expansion with 100 MW high-performance computing target), CURI -0.6% (names new CFO), IMRX -0.2% (shares comments following FDA approval of a new second-line pancreatic cancer treatment)